Lichen planus is an autoimmune-mediated chronic inflammatory disease of unknown etiology, but studies have reported the role of cytotoxic T cells responsible for the disruption of basal keratinocytes and also causing the clinical symptoms. It is commonly seen in adults, with rare occurrence in children. It clinically manifests on the skin and oral mucosa, with skin lesions healing faster than the oral lesions. To obtain a diagnosis, a complete history and characteristic clinical features are usually sufficient for diagnosis, but there are certain other lesions like lichenoid reaction, contact sensitivity, white sponge nevus, pemphigoid and lupus erythematosus that show similar clinical characteristics, hence the need for histopathological evaluation using standard criteria given by Krutchkoff or World Health Organization (WHO). The treatment administered is always for eliminating symptoms and discomfort of the patients. A variety of pharmacological and natural alternatives have been used, along with frequent follow up visits in case of a tropic and erosive lichen planus. The purpose of this paper is to review the current trends in the management of oral lichen planus.
INTRODUCTION
Oral lichen planus (OLP) is a chronic mucocutaneous disease of multifactorial etiologies with Wilson first describing it in 1869. It was suggested by authors to an autoimmune disease triggered by antigens in the form of extrinsic or intrinsic factors that activate the lymphocytes and releases cytokines that are directed against the basilar keratinocytes leading to their apoptosis. It was seen to affect 0.5-1% of the worldwide population and 0.1-1.5% prevalence in India. 1 The condition affects the cutaneous or mucosal areas or both, where 50% of individuals with cutaneous lichen planus had oral mucosal lesions, and about 25% presented with, oral mucosal lesions alone. 2 It was seen most commonly in adults and had a female prediliction. 3 An OLP commonly affects the buccal mucosa, gingiva, and the tongue, with an uncommon presentation on the palate. 4 It is usually seen as multiple lesions, bilaterally present in the mouth persisting for a longer duration of up to 25 years in comparison to the cutaneous counterpart. 5, 6 It shows a chronic course having periods of dormancy and flare-ups with spontaneous remissions rarely seen. 7 Andreasen 2 divided oral lichen planus into six clinical types: reticular, plaque-like, papular, erosive, bullous, and atrophic types where erosive and atrophic types caused discomfort and painful symptoms. On clinical examination, in the absence of the reticular type which is easily identifiable, the other types of oral lichen planus requires histopathological evaluation for a definite diagnosis. This is done using WHO criteria (2003) for diagnosis of OLP, that includes clinical criteria's, histopathological criteria's and final differentiation of lichen planus from lichenoid lesions. 8 An OLP is a disease with a potential for malignant transformation. It has been noted that the rate of malignant transformation has decreased from 5.9% in 1924 to 0.5-1.1% in 2017. 9 However, this possibility may be reduced by patient counseling, consumption of a healthy diet and avoiding carcinogens. 10 The standard protocol for the management of oral lichen planus includes symptomatic relief with no complete cure. Various alternatives have been applied in the management which suggests the inadequacy of any single drug to provide relief. The present article hereby provides an overview of different treatment modalities in the management and the advancements made in obtaining control over the symptoms of OLP. The OLP could be symptomatic (erosive, atrophic and bullous types) or asymptomatic (reticular or plaque types). The symptomatic oral lichen planus can cause a burning sensation, severe pain, inability to speak and swallow, which is seen to be the chief complaint of the patient requiring symptomatic relief 11 while the asymptomatic forms do not require pharmacological interven-
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tion. The treatment plan is formulated according to the psychological state, medical history of drug interactions and drug compliance of the patient. 12 The most accepted treatment protocol for OLP is depicted in Flow Chart 1.
The treatment plan consisting of pharmacological therapy includes antifungals (Table 1) , corticosteroids (Table 2 ), immunosuppressant's (Table 3 ) and other systemic drugs (Table 4) , whereas, the other treatment modalities include nonpharmacological therapy (Table 5 ), natural alternatives (Table 6 ) and surgery.
Pharmacological Therapy

Antifungals
Candida albicans is seen to be present in 37% of the OLP lesions (superimposed candidal infections) which exacerbates it and produces symptoms. This could be because, in erosive lesions on the gingiva or oral mucosa, maintenance of oral hygiene is difficult leading to fungal infections. Another reason can be the prolonged use of corticosteroids, which leads to decrease in the immune mechanism of the mucosa and also reduces the salivary flow, leading to altered microflora and hence enhanced candida growth in the oral cavity. 13 Infection and inflammation caused by Candida was seen to show changes in the epithelium which was histopathologically misdiagnosed as dysplasia. 14 Hence an antifungal therapy is advised (Table 1) as it can change the erosive form of OLP into reticular forms. 15 The antifungal griseofulvin was used by Sehgal in 1972 and was found to be useful in the management of oral LP, unlike others who found no improvements in the lesion. 16 Symptomatic relief was reported on using other antifungals like amphotericin B, azoles and nystatin. The use of topical miconazole was also found to be an effective antifungal against candidal superinfections during topical steroid therapy. 17 The use of clobetasol showed greater chances of oral fungal infection than any other steroid therapy; hence an accompanying antifungal (clotrimazole)could be used as it produced greater symptom relief than any other antifungal. 18 
Corticosteroids
Corticosetroids in the form of topical agents, intralesional injections and systemic drugs is considered to be the mainstay of the treatment of oral lichen planus. The details about the drugs used and its mechanism of action with adverse effects is mentioned in Table 2 .
Immunosuppressans and Other Systemic Drugs
Immunosuppressant's are the agents used to suppress the immune mechanism that targets and damages the host. The details of the immunosuppressant's as well as the other systemic drugs that are used in the management of oral lichen planus along with their mechanism of action, dosage and adverse effects is mentioned in Tables 3 and 4 .
Nonpharmacological Therapy
Several nonpharmacological modalities have been used for the treatment of recalcitrant oral lichen planus have been discussed in Table 5 .
Natural Alternatives
The current drug treatments seem to be only palliative and have also shown to have various adverse effects, hence, valuable natural therapies have been inculcated for effective treatment of oral lichen planus. The details of the natural agents used with their mechanism of action and dosages have been discussed in Table 6 .
Flow Chart 1: Treatment protocol for oral lichen planus 
Surgery
Surgical excision of the lesional tissue should not be considered as the primary treatment modality because lichen planus is an inflammatory disease which will reoccur. Its application for multicentric lesions, erosive and atopic oral lichen planus was not advisable as the surface epithelium is eroded. Laser ablation using carbon dioxide and cryosurgery is considered in erosive oral lichen planus resistant to most treatment modalities. Surgery is advisable in plaque type of lichen planus as the superficial layer of the lesion can easily be removed. Localized erosive oral lichen planus lesions also were seen showing complete eradication of symptoms following treatment with a free gingival graft after a follow-up of 3.5 years. 
Hyaluronic acid
It enhances healing by forming a protective coat in the mucosa and thus keeping it hydrated. PUVA can effect specifically lymphocytes or PMNL.
0.2% gel
It causes immunologic alterations hence decreasing the levels of lymphocytes.
30 Dose: Methoxypsoralen is given orally, followed by administration of 2 hours of UV radiation intraorally in the affected sites.
Initial UVA dose was 1.5-2 J/cm 2 and was increased at the first and third sessions of each week.
The maximum dose administered at the end of treatment never exceeded 7 J/cm 2 in a single session.
Treated three times per week with an interval of 48 h between each session.
Patient's tolerance to UVA permitted, the number of weekly sessions was progressively increased to 4 and subsequently 5. The lasers used were 904 nm pulsed infrared laser (four sessions weekly) and 980 nm gallium-aluminumarsenide diode laser. 35, 36 Erythema, soreness 
Contributing Etiological Factor in Oral Lichen Planus
Psychological Influence
Oral lichen planus (OLP) was considered by researchers as a psychosomatic disorder whose occurrence was influenced by the conditions of stress, anxiety or depression or was considered as etiologic factors to OLP. 44, 45 A positive relation of oral lichen planus with the psychological status of an individual was noted. In 1998 studies had shown a greater incidence of OLP in people with a higher degree Contd... of anxiety, depression, and psychic disorders. 46 On the contrary, the incidence of the lesion with their severity was also linked to the psychological condition of an individual. A long-term symptomatic lesion of lichen planus could lead to anxiety, tiredness, increased stress and cancerophobia in patients, which directly affects the everyday life of a person and also their attitude towards the disease. A prolonged disease state in an individual lead to the use of catastrophizing or strategies to cope with the intensity of pain, which in turn was seen affecting the lifestyle of the individual. 47 In such cases exacerbating factors should be minimized, stress management, breathing exercise, and yoga should be practiced.
